|
CCX832 is an orally active molecule antagonist of chemerin at the chemokine receptor CMKLR1(ChemR2). ChemoCentryx, a pharmaceutical firm based in California, announced in April 2010 that they were successful in developing this medication in alliance with GlaxoSmithKline(GSK). == References == 抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「CCX832」の詳細全文を読む スポンサード リンク
|